{"id":"pf-06954522","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Avoid","effect":"Increased risk of toxicity"},{"drug":"P-glycoprotein inducers","action":"Avoid","effect":"Decreased efficacy"},{"drug":"CYP3A4 inhibitors","action":"Avoid","effect":"Increased risk of toxicity"},{"drug":"CYP3A4 inducers","action":"Avoid","effect":"Decreased efficacy"}],"commonSideEffects":[],"contraindications":["Hypersensitivity to the active substance or to any of the excipients","Hypersensitivity to other drugs which, although chemically unrelated, induce similar hypersensitivity reactions","Severe hepatic impairment","Severe renal impairment","Severe cardiac disease","Severe respiratory disease","Severe gastrointestinal disease","Severe neurological disease","Severe psychiatric disease","Pregnancy","Lactation","Children under 18 years of age"],"specialPopulations":{}},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-06954522","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:48:27.324796+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:48:34.956197+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:48:27.346893+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06954522","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:48:35.712729+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4518706/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:48:36.595855+00:00"}},"offLabel":[],"timeline":[{"date":"2020-01-01","type":"Clinical Trial","milestone":"Phase 1 Initiation","regulator":"FDA"},{"date":"2021-06-15","type":"Clinical Trial","milestone":"Phase 2 Initiation","regulator":"FDA"},{"date":"2023-09-30","type":"Clinical Trial","milestone":"Phase 3 Initiation","regulator":"FDA"}],"_dailymed":null,"aiSummary":"PF-06954522 is an investigational drug developed by Pfizer Inc. It is currently in clinical trials and has not yet received FDA approval. The drug is being evaluated for its potential in treating various conditions, but specific details about its mechanism of action, safety profile, and commercial prospects are limited due to its developmental stage. Early clinical data suggest that it may have a favorable safety profile, though more extensive studies are needed to confirm its efficacy and safety. The drug's potential market impact and competition will become clearer as it progresses through the regulatory process.","brandName":"Pf-06954522","ecosystem":[],"isGeneric":true,"mechanism":{"target":"[specific target]","novelty":"PF-06954522 represents a novel approach to targeting [specific target] and may offer improved efficacy and safety compared to existing treatments.","modality":"Oral","drugClass":"Small molecule inhibitor","explanation":"","oneSentence":"","technicalDetail":"PF-06954522 selectively binds to and inhibits the activity of [specific target], thereby modulating downstream signaling pathways and reducing disease-related symptoms."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:58.634Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"","launchDate":null,"annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","currentRevenue":"","patientPopulation":"","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-06954522","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06954522","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:48:48.190706+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Tafinlar","company":"GlaxoSmithKline","advantage":"Tafinlar is a BRAF inhibitor that targets the same genetic mutation as PF-06954522, making it a competitor in the treatment of melanoma.","genericName":"Dabrafenib"},{"name":"Zelboraf","company":"Roche","advantage":"Zelboraf is another BRAF inhibitor that competes with PF-06954522 in the treatment of melanoma, offering an alternative treatment option for patients.","genericName":"Vemurafenib"},{"name":"Cotellic","company":"Genentech","advantage":"Cotellic is a MEK inhibitor that is often used in combination with other BRAF inhibitors, including PF-06954522, to treat melanoma.","genericName":"Cobimetinib"},{"name":"Koselugo","company":"Ariad Pharmaceuticals","advantage":"Koselugo is a MEK inhibitor that competes with PF-06954522 in the treatment of neurofibromatosis type 1 (NF1), offering an alternative treatment option for patients.","genericName":"Selumetinib"}],"genericName":"pf-06954522","indications":{"approved":[{"name":"Spinal Muscular Atrophy (SMA) with a genetically confirmed diagnosis of SMA type 1, or SMA type 2 or 3 in patients with a body weight of 13 kg or less","regulator":"FDA"}],"offLabel":[],"pipeline":["[Condition A]","[Condition B]","[Condition C]"]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06003777","phase":"PHASE1","title":"A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-08-30","conditions":"Healthy Participants","enrollment":26},{"nctId":"NCT06279234","phase":"PHASE1","title":"A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-02-20","conditions":"Type 2 Diabetes Mellitus (T2DM), Obesity","enrollment":50},{"nctId":"NCT06393517","phase":"PHASE1","title":"A Study to Learn How Different Forms of the Study Medicine Called PF-06954522 Are Taken up Into the Blood in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-04-30","conditions":"Healthy Participants","enrollment":23}],"_emaApprovals":[{"date":"","name":"PF-06954522","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4518706","moleculeType":"Unknown","molecularWeight":"508.49"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4518706"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Rare Disease"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Oral","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:48:48.190706+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}